Name | Donanemab |
---|
Description | Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2]. |
---|---|
Related Catalog | |
In Vitro | Donanemab 是一种针对 N 末端焦谷氨酸 Aβ 表位的人源化 IgG1 抗体,该表位仅存在于已建立的斑块中。Donanemab 对该表位具有特异性,并且未显示与其他 Aβ 种类、神经递质或其受体的脱靶结合[2]。 |
References |
No Any Chemical & Physical Properties |